Compare Stocks: LUCD, CLYM, FDMT, and MNPR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$14.59 -3.1%	$13.99	$1.54 ▼ $18.33	$864.42M	0.09	1.36 million shs	5.53 million shs
FDMT 4D Molecular Therapeutics	$14.70 -1.6%	$12.47	$6.09 ▼ $16.93	$825.35M	2.74	1.12 million shs	781,569 shs
LUCD Lucid Diagnostics	$0.95 -3.9%	$0.98	$0.86 ▼ $1.63	$201.19M	1.1	781,186 shs	837,445 shs
MNPR Monopar Therapeutics	$118.55 +2.0%	$109.18	$35.01 ▼ $124.82	$780.49M	1.49	204,147 shs	208,564 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-3.06%	-3.12%	+16.16%	+38.29%	+497.95%
FDMT 4D Molecular Therapeutics	-1.61%	-1.41%	+43.27%	+70.14%	+127.20%
LUCD Lucid Diagnostics	-3.91%	-3.33%	-0.83%	-1.65%	-23.29%
MNPR Monopar Therapeutics	+1.95%	+4.05%	+0.08%	+99.31%	+227.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$14.59 -3.1%	$13.99	$1.54 ▼ $18.33	$864.42M	0.09	1.36 million shs	5.53 million shs
FDMT 4D Molecular Therapeutics	$14.70 -1.6%	$12.47	$6.09 ▼ $16.93	$825.35M	2.74	1.12 million shs	781,569 shs
LUCD Lucid Diagnostics	$0.95 -3.9%	$0.98	$0.86 ▼ $1.63	$201.19M	1.1	781,186 shs	837,445 shs
MNPR Monopar Therapeutics	$118.55 +2.0%	$109.18	$35.01 ▼ $124.82	$780.49M	1.49	204,147 shs	208,564 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	-3.06%	-3.12%	+16.16%	+38.29%	+497.95%
FDMT 4D Molecular Therapeutics	-1.61%	-1.41%	+43.27%	+70.14%	+127.20%
LUCD Lucid Diagnostics	-3.91%	-3.33%	-0.83%	-1.65%	-23.29%
MNPR Monopar Therapeutics	+1.95%	+4.05%	+0.08%	+99.31%	+227.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.00	Buy	$25.62	75.57% Upside
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$29.63	101.53% Upside
LUCD Lucid Diagnostics	2.60	Moderate Buy	$4.19	340.23% Upside
MNPR Monopar Therapeutics	2.86	Moderate Buy	$118.67	0.10% Upside

Current Analyst Ratings Breakdown

Latest LUCD, CLYM, FDMT, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	CLYM Climb Bio	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$40.00
9/3/2026	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $25.00
9/3/2026	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $32.00
8/24/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $24.00
8/19/2026	CLYM Climb Bio	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
8/18/2026	LUCD Lucid Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	MNPR Monopar Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$130.00
8/17/2026	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.50
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/13/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$125.00 ➝ $128.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$4.17 per share	N/A
FDMT 4D Molecular Therapeutics	$85.21M	9.53	N/A	N/A	$7.38 per share	1.99
LUCD Lucid Diagnostics	$4.71M	41.04	N/A	N/A	$0.05 per share	19.02
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$19.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/5/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
LUCD Lucid Diagnostics	-$58.01M	-$0.47	N/A	N/A	N/A	-959.76%	N/A	-119.57%	11/11/2026 (Estimated)
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	11/12/2026 (Estimated)

Latest LUCD, CLYM, FDMT, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/13/2026	Q2 2026	LUCD Lucid Diagnostics	-$0.0567	-$0.06	-$0.0033	-$0.08	$1.43 million	$1.47 million
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	31.45	31.45
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
LUCD Lucid Diagnostics	N/A	1.33	1.31
MNPR Monopar Therapeutics	N/A	33.56	33.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
FDMT 4D Molecular Therapeutics	99.27%
LUCD Lucid Diagnostics	74.01%
MNPR Monopar Therapeutics	1.83%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	2.60%
FDMT 4D Molecular Therapeutics	7.90%
LUCD Lucid Diagnostics	6.90%
MNPR Monopar Therapeutics	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	57.44 million	55.94 million	N/A
FDMT 4D Molecular Therapeutics	120	55.24 million	50.88 million	Optionable
LUCD Lucid Diagnostics	70	203.24 million	189.22 million	No Data
MNPR Monopar Therapeutics	10	6.71 million	6.06 million	Not Optionable

LUCD, CLYM, FDMT, and MNPR Headlines

Recent News About These Companies

Bank of America Corp DE Buys 53,336 Shares of Monopar Therapeutics Inc. $MNPR

August 31, 2026 | marketbeat.com

Insider Selling: Monopar Therapeutics (NASDAQ:MNPR) Director Sells 3,142 Shares of Stock

August 28, 2026 | insidertrades.com

Raymond Anderson Sells 3,142 Shares of Monopar Therapeutics (NASDAQ:MNPR) Stock

August 27, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Director Sells $455,585.10 in Stock

August 27, 2026 | marketbeat.com

Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 22, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Trading Down 3.9% - Time to Sell?

August 21, 2026 | marketbeat.com

MNPR FY2026 EPS Estimate Lifted by Brookline Capital Markets

August 20, 2026 | marketbeat.com

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

August 19, 2026 | markets.businessinsider.com

Monopar Appoints Jeffrey D. Kent, M.D.

August 19, 2026 | globenewswire.com

Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'

August 18, 2026 | seekingalpha.com

Q3 EPS Estimate for Monopar Therapeutics Cut by Analyst

August 17, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen

August 16, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), Achieve Life Sciences (ACHV) and OptimizeRx (OPRX)

August 15, 2026 | theglobeandmail.com

Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold

August 15, 2026 | marketbeat.com

Equities Analysts Offer Predictions for MNPR FY2029 Earnings

August 14, 2026 | marketbeat.com

Monopar cut to neutral at Cantor on valuation

August 13, 2026 | msn.com

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 12, 2026 | markets.businessinsider.com

BTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock

August 12, 2026 | marketbeat.com

Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS

August 12, 2026 | marketbeat.com

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update on ALXN1840 NDA Submission

August 12, 2026 | quiverquant.comQ

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, CLYM, FDMT, and MNPR Company Descriptions

Climb Bio NASDAQ:CLYM

$14.59 -0.46 (-3.06%)

As of 09/3/2026 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

4D Molecular Therapeutics NASDAQ:FDMT

$14.70 -0.24 (-1.61%)

As of 09/3/2026 04:00 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Lucid Diagnostics NASDAQ:LUCD

$0.95 -0.04 (-3.91%)

As of 09/3/2026 04:00 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Monopar Therapeutics NASDAQ:MNPR

$118.55 +2.27 (+1.95%)

As of 09/3/2026 04:00 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LUCD, CLYM, FDMT, and MNPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LUCD, CLYM, FDMT, and MNPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LUCD, CLYM, FDMT, and MNPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, CLYM, FDMT, and MNPR Company Descriptions

Climb Bio NASDAQ:CLYM

4D Molecular Therapeutics NASDAQ:FDMT

Lucid Diagnostics NASDAQ:LUCD

Monopar Therapeutics NASDAQ:MNPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LUCD, CLYM, FDMT, and MNPR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LUCD, CLYM, FDMT, and MNPR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LUCD, CLYM, FDMT, and MNPR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, CLYM, FDMT, and MNPR Company Descriptions

Climb Bio NASDAQ:CLYM

4D Molecular Therapeutics NASDAQ:FDMT

Lucid Diagnostics NASDAQ:LUCD

Monopar Therapeutics NASDAQ:MNPR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools